Maze Therapeutics, Inc. — All Filings
140 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
424B3
424B4
8-A12B
8-K
CERT
CORRESP
DRS
DRS/A
DRSLTR
EFFECT
S-1
S-1/A
S-1MEF
S-3ASR
S-8
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | — | 0002050172-25-000004 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0002050422-25-000004 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001238403-25-000005 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001555132-25-000005 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001214133-25-000007 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001283290-25-000005 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001864112-25-000004 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001192591-25-000005 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001620014-25-000005 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001804999-25-000005 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001214133-25-000005 | Sep 16, 2025 | Sep 15, 2025 |
| 144 | — | 0001950047-25-007109 | Sep 15, 2025 | — |
| 8-K | 8-K | 0001193125-25-200760 | Sep 11, 2025 | Sep 10, 2025 |
| 4 | — | 0001415889-25-023463 | Sep 2, 2025 | — |
| 3 | — | 0001415889-25-023462 | Sep 2, 2025 | — |
| 8-K | 8-K | 0001193125-25-193353 | Sep 2, 2025 | — |
| 4 | — | 0001415889-25-022301 | Aug 19, 2025 | Aug 17, 2025 |
| SCHEDULE 13G/A | — | 0001415889-25-021795 | Aug 14, 2025 | — |
| SCHEDULE 13G/A | — | 0001172661-25-003264 | Aug 14, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-107306 | Aug 12, 2025 | Jun 30, 2025 |
| 8-K | 8-K | 0000950170-25-107299 | Aug 12, 2025 | — |
| SCHEDULE 13G | — | 0001072613-25-000407 | May 15, 2025 | — |
| SCHEDULE 13G | — | 0000902664-25-002323 | May 14, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-071375 | May 14, 2025 | Mar 31, 2025 |
| 8-K | 8-K | 0000950170-25-071357 | May 14, 2025 | — |
| SCHEDULE 13G | — | 0001415889-25-012489 | May 9, 2025 | — |
| SCHEDULE 13G | — | 0000950170-25-068039 | May 9, 2025 | — |
| SCHEDULE 13G/A | — | 0001415889-25-011451 | Apr 29, 2025 | — |
| SCHEDULE 13G/A | — | 0001415889-25-011448 | Apr 29, 2025 | — |
| 10-K | 10-K | 0000950170-25-047208 | Mar 31, 2025 | Dec 31, 2024 |
| 8-K | 8-K | 0000950170-25-047207 | Mar 31, 2025 | — |
| SCHEDULE 13G | — | 0001415889-25-003423 | Feb 10, 2025 | — |
| SCHEDULE 13G | — | 0001172661-25-000583 | Feb 7, 2025 | — |
| SCHEDULE 13G | — | 0001104659-25-010521 | Feb 7, 2025 | — |
| SCHEDULE 13G | — | 0001104659-25-010518 | Feb 7, 2025 | — |
| SEC STAFF LETTER | — | 9999999997-25-000302 | Feb 6, 2025 | — |
| 4 | 4 | 0000950170-25-013760 | Feb 4, 2025 | Feb 3, 2025 |
| 4 | — | 0001415889-25-002957 | Feb 4, 2025 | Feb 3, 2025 |
| 4 | — | 0001415889-25-002956 | Feb 4, 2025 | Feb 3, 2025 |
| S-8 | S-8 | 0001193125-25-018493 | Jan 31, 2025 | — |
| 424B4 | 424B4 | 0001193125-25-018482 | Jan 31, 2025 | — |
| EFFECT | — | 9999999995-25-000242 | Jan 30, 2025 | — |
| 3 | 3 | 0000950170-25-011306 | Jan 30, 2025 | — |
| S-1MEF | S-1MEF | 0001193125-25-017403 | Jan 30, 2025 | — |
| 3 | — | 0001415889-25-002383 | Jan 30, 2025 | — |
| 3 | — | 0001415889-25-002382 | Jan 30, 2025 | — |
| 3 | — | 0001415889-25-002381 | Jan 30, 2025 | — |
| 3 | — | 0001415889-25-002380 | Jan 30, 2025 | — |
| 3 | — | 0001415889-25-002379 | Jan 30, 2025 | — |
| 3 | — | 0001415889-25-002378 | Jan 30, 2025 | — |